Article
Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology.
BioMed research international - 1 Jan 2013
Roma Cristin, Esposito Claudia, Rachiglio Anna Maria, Pasquale Raffaella, Iannaccone Alessia, Chicchinelli Nicoletta, Franco Renato, Mancini Rita, Pisconti Salvatore, De Luca Antonella, Botti Gerardo, Morabito Alessandro, Normanno Nicola
Abstract excerpt
Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are predictive of response to treatment with tyrosine kinase inhibitors. Competitive Allele-Specific TaqMan PCR (castPCR) is a highly sensitive and specific technology. EGFR mutations were assessed by TaqMan Mutation Detection Assays (TMDA) based on castPCR technology in 64 tumor samples: a training set of 30 NSCLC and 6...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
